Follistatin-315

Muscle Function

Early research produced the "mighty mouse," an experimental model with four times the muscle mass of controls. Knocking out the myostatin gene alone doubled muscle mass, while the dual approach of myostatin knockout combined with follistatin overexpression quadrupled it, indicating follistatin acts through multiple pathways beyond myostatin inhibition alone (Lee, 2007).

In mouse models of spinal muscular atrophy (SMA), follistatin administration improved skeletal muscle mass, ventral horn cell numbers, motor function, and extended survival by approximately 30% compared to untreated controls (Rose et al., 2009).

Testing in non-human primates showed that follistatin can boost muscle growth in the setting of inclusion body myositis, an inflammatory disease that damages muscle cells and promotes myostatin release.

Blood Vessel Growth

Follistatin and activin have opposing effects on different cell types. Activin boosts smooth muscle proliferation but inhibits endothelial cell growth. Endothelial cells naturally express follistatin during early development to counteract activin A. Research demonstrates that follistatin enhances endothelial cell function during injury responses, with injection in ischemic settings boosting blood vessel function and restoring blood flow (Kelaini et al., 2018).

Kidney Disease

The combination of anti-inflammatory and pro-angiogenic properties prompted investigation into kidney disease. In mouse models, follistatin administration reduced cell death, oxidative damage, and overall scarring (Mehta et al., 2019), suggesting potential to slow chronic kidney disease progression and delay the need for dialysis or transplant.

Biomarker Applications

Follistatin levels increase significantly with cardiovascular disease onset, raising the possibility of using it as an early disease marker (Lee et al., 2019). In late-stage disease, elevated follistatin correlates with left ventricular remodeling, potentially aiding clinical decisions in heart failure management (El-Armouche et al., 2011).

Protein Engineering

Research on follistatin has provided a model for altering naturally occurring proteins for therapeutic purposes. Synthetic follistatin variants with improved pharmacokinetic characteristics have been developed, laying groundwork for more predictable protein engineering approaches (Shen et al., 2018).

Inflammation

Research in mice with rheumatoid arthritis has demonstrated that overexpression of activin A or under-expression of follistatin worsens disease, while follistatin supplementation reverses clinical signs and symptoms (Diller et al., 2019).

In asthma, elevated activin A levels correlate with disease severity markers (Papaporfyriou et al., 2017). Intranasal follistatin administration in mice inhibits airway remodeling commonly seen in asthma (Hardy et al., 2013), suggesting potential applications in asthma, sarcoidosis, idiopathic pulmonary fibrosis, and failed lung transplants linked to activin A dysregulation.

Follistatin has also been shown to attenuate fibrosis associated with radiation therapy, reducing epidermal thickness changes and expression of TGF-beta and smooth muscle actin (Forrester et al., 2017). In bleomycin-induced pulmonary fibrosis, follistatin reduced cell infiltration of lung tissues and attenuated fibrosis for up to one month post-injection (Aoki et al., 2005).

Extensive review has established activin's role in cachexia, septicemia, and fibrosis, positioning follistatin as a potential treatment for a range of inflammatory conditions (Hedger et al., 2011).

Myostatin/activin blockade

Follistatin is an endogenous antagonist of myostatin and activins; the FS315 (serum) isoform has lower heparin/cell-surface binding than FS288, favoring circulating activity for systemic muscle growth signaling.

• AAV-delivered follistatin increased muscle mass and strength in preclinical models and early BMD patients
• FS344 mRNA is post-translationally modified to FS315, the predominant serum form

Muscle-wasting therapeutics

Follistatin gene and protein strategies target dystrophies, myopathies, and sarcopenia by increasing muscle fiber size and reducing fibrosis, but off-target activin effects and durability remain under study.

• First gene therapy to show functional improvement in a muscular dystrophy
• Rigorous controlled efficacy data are still lacking beyond small early-phase cohorts